From Multiomics to Clinical Intelligence: Volv Global at Frontiers Health 2026
Volv Global at Frontiers Health's panel on AI & biomarker science translating complex biological signals into cli...
Volv Global provides data-driven understanding of disease endpoints and outcomes to support pricing and reimbursement calculations, regulatory and HTA submissions, payer evidence packages and comparative economics studies with real-world evidence.
Analyse real-world treatment pathways and their effectiveness to define more precise endpoints for better analysis of disease progression and outcomes.
Compare treatment effectiveness via analysis of real-world outcomes of different intervention.
Identify cohorts more precisely and at an early stage for better longitudinal assessment of patient health outcomes.
Understand the real-world impact on quality of life and healthcare utilisation for payer evidence packages and comparative economic studies
Value, access and HEOR in the face of complexity
Integrating real-world evidence (RWE) to understand the real-world clinical, economic, and social impact of disease on quality of life and healthcare utilisation.
Disparate healthcare systems and patient populations create inconsistent datasets lacking standardised outcome measures.
Linking medical records to cost-related data is often difficult.
Differences in healthcare access across regions affect generalisability of findings.
Supporting Value and Access, HEOR
Growing the real-world evidence on a disease, and a clearer view of how many people it affects.
Studying the early biomarker patterns that precede a condition, sometimes years before conventional signs appear.
Modelling how disease progresses across diagnosed populations, using real-world evidence.
Sizing the diagnosed population not yet on treatment, and showing where the gap to care opens.
Leading AI/ML methodology to support Value and Access, HEOR
Through comprehensive data integration from clinical and claims sources, our proprietary machine learning methodology equips Value & Access and HEOR teams to quantify the real-world performance of therapies.
By merging clinical, claims, and other healthcare data, our methodology provides a holistic view of disease burden, allowing for robust cost-effectiveness and outcomes analyses.
This data-backed insight aids stakeholders in demonstrating value to payers, supporting the evidence case for earlier diagnosis and wider patient access.
Shaping the future today
Volv Global at Frontiers Health's panel on AI & biomarker science translating complex biological signals into cli...
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global at the 25th Annual NEALS Meeting, presenting new research on early identification of ALS using advanced M...
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
The next useful thing AI does in solid tumour care is about timing, not detection. The patient must reach the right t...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
ASCO 2026 produced landmark oncology data. The question no one asked from the podium: can clinical infrastructure get...
Drive For Change white paper: three paradigm shifts to unlock orphan drug development
Approximately 95% of rare diseases have no approved treatment. Drive For Change identifies three structural paradigms...